Enovis Corporation $ENOV Shares Acquired by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd lifted its stake in Enovis Corporation (NYSE:ENOV) by 82.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 25,700 shares of the company’s stock after purchasing an additional 11,640 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in Enovis were worth $806,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Enovis by 11.3% in the 1st quarter. Vanguard Group Inc. now owns 6,107,199 shares of the company’s stock valued at $233,356,000 after buying an additional 621,069 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Enovis by 191.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 810,771 shares of the company’s stock valued at $26,772,000 after acquiring an additional 532,648 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Enovis by 43.8% in the second quarter. Geode Capital Management LLC now owns 1,342,481 shares of the company’s stock valued at $42,105,000 after purchasing an additional 408,608 shares during the period. Invenomic Capital Management LP increased its position in Enovis by 199.6% during the first quarter. Invenomic Capital Management LP now owns 449,777 shares of the company’s stock worth $17,186,000 after purchasing an additional 299,658 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY raised its stake in Enovis by 47.5% during the first quarter. Paradigm Capital Management Inc. NY now owns 786,400 shares of the company’s stock worth $30,048,000 after purchasing an additional 253,200 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Wall Street Analyst Weigh In

ENOV has been the subject of several analyst reports. UBS Group dropped their price target on shares of Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Canaccord Genuity Group reduced their target price on Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Needham & Company LLC lowered their price target on Enovis from $57.00 to $49.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Finally, Wells Fargo & Company raised their price objective on Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $51.17.

Insider Activity at Enovis

In other Enovis news, CEO Damien Mcdonald acquired 6,457 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The stock was purchased at an average price of $30.97 per share, for a total transaction of $199,973.29. Following the completion of the acquisition, the chief executive officer owned 102,753 shares of the company’s stock, valued at approximately $3,182,260.41. This trade represents a 6.71% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.70% of the company’s stock.

Enovis Trading Up 7.2%

Shares of NYSE ENOV opened at $28.77 on Friday. The company has a current ratio of 2.25, a quick ratio of 1.15 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $1.65 billion, a PE ratio of -2.02 and a beta of 1.67. Enovis Corporation has a twelve month low of $25.47 and a twelve month high of $49.75. The stock has a fifty day simple moving average of $30.95 and a 200-day simple moving average of $31.10.

Enovis (NYSE:ENOV) last announced its earnings results on Monday, January 8th. The company reported $0.59 EPS for the quarter. The company had revenue of $383.81 million during the quarter. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%. On average, equities analysts forecast that Enovis Corporation will post 2.79 earnings per share for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.